Syndax(US:SNDX) Globenewswire·2025-05-14 13:30Core Insights - Syndax Pharmaceuticals announced the acceptance of multiple abstracts for clinical data presentations of Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) at the 30th European Hematology Association (EHA) Annual Congress Meeting scheduled for June 12-15, 2025, in Milan, Italy [1][2] Group 1: Revuforj® (revumenib) - Revuforj is a first-in-class selective menin inhibitor approved for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged one year and older [10][11] - The BEAT AML frontline trial data will be presented, showcasing the combination of revumenib with venetoclax and azacitidine in patients with mNPM1 and KMT2Ar AML [2][6] - Compelling results in acute leukemia across various genetic populations, including mNPM1 and KMT2Ar, will be highlighted [5][6] Group 2: Niktimvo™ (axatilimab-csfr) - Niktimvo is a first-in-class CSF-1R-blocking antibody approved for chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy [12][35] - The AGAVE-201 trial data will be presented, demonstrating robust responses in different organs and patient subgroups with chronic GVHD [5][8] - Ongoing studies include a Phase 2 combination trial with ruxolitinib and a Phase 3 trial with steroids for chronic GVHD [14][35]